drugset / Trial / NCT03429049

A Phase 3 Efficacy and Safety Study of Intra-articular CNTX-4975-05 (Capsaicin) vs Placebo in Subjects With OA Knee Pain

NCT03429049

Phase 3 Completed 332 enrolled Centrexion Therapeutics
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a phase 3, randomized, double-blind, placebo-controlled, single injection, 52-week study to evaluate the analgesic efficacy and safety of a single intra-articular (IA) CNTX-4975-05 (capsaicin), compared to IA placebo, in subjects with chronic, moderate-to-severe osteoarthritis (OA) knee pain.

Timeline

Start
2018-01-24
Primary completion
2019-11-22
Completion
2019-11-22

Drugs

EvaluationDrugModalityDoseRoute
Subject CNTX-4975-05 Unknown Other

Indications